Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Feras W. Darwish Elhajji is active.

Publication


Featured researches published by Feras W. Darwish Elhajji.


Journal of Antimicrobial Chemotherapy | 2012

An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings

Mamoon A. Aldeyab; Mary P. Kearney; Michael G. Scott; Motasem A. Aldiab; Yaser M. Alahmadi; Feras W. Darwish Elhajji; Fidelma A. Magee; James McElnay

OBJECTIVES To evaluate the impact of a high-risk antibiotic stewardship programme on reducing antibiotic use and on hospital Clostridium difficile infection (CDI) incidence rates. A secondary objective was to present the possible utility of time-series analysis as an antibiotic risk classification tool. METHODS This was an interventional, retrospective, ecological investigation in a medium-sized hospital over 6.5 years (January 2004 to June 2010). The intervention was the restriction of high-risk antibiotics (second-generation cephalosporins, third-generation cephalosporins, fluoroquinolones and clindamycin). Amoxicillin/clavulanic acid and macrolides were classified as medium-risk antibiotics based on time-series analysis findings and their use was monitored. The intervention was evaluated by segmented regression analysis of interrupted time series. RESULTS The intervention was associated with a significant change in level of use of high-risk antibiotics (coefficient -17.3, P < 0.0001) and with a borderline significant trend change in their use being reduced by 0.156 defined daily doses/100 bed-days per month (P = 0.0597). The reduction in the use of high-risk antibiotics was associated with a significant change in the incidence trend of CDI (P = 0.0081), i.e. the CDI incidence rate decreased by 0.0047/100 bed-days per month. Analysis showed that variations in the incidence of CDI were affected by the age-adjusted comorbidity index with a lag of 1 month (coefficient 0.137051, P = 0.0182). Significant decreases in slope (coefficient -0.414, P = 0.0309) post-intervention were also observed for the monitored medium-risk antibiotics. CONCLUSIONS The restriction of the high-risk antibiotics contributed to both a reduction in their use and a reduction in the incidence of CDI in the study site hospital. Time-series analysis can be utilized as a risk classification tool with utility in antibiotic stewardship design and quality improvement programmes.


Infection Control and Hospital Epidemiology | 2011

Multihospital Outbreak of Clostridium difficile Ribotype 027 Infection: Epidemiology and Analysis of Control Measures

Mamoon A. Aldeyab; Michael J. Devine; Peter Flanagan; Michael Mannion; Avril Craig; Michael G. Scott; Stéphan Juergen Harbarth; Nathalie Vernaz; Elizabeth Davies; Jon S. Brazier; Smyth B; James McElnay; Brendan F. Gilmore; Geraldine Conlon; Fidelma A. Magee; Feras W. Darwish Elhajji; Shaunagh Small; Collette Edwards; Chris Funston; Mary P. Kearney

OBJECTIVE To report a large outbreak of Clostridium difficile infection (CDI; ribotype 027) between June 2007 and August 2008, describe infection control measures, and evaluate the impact of restricting the use of fluoroquinolones in controlling the outbreak. DESIGN Outbreak investigation in 3 acute care hospitals of the Northern Health and Social Care Trust in Northern Ireland. INTERVENTIONS Implementation of a series of CDI control measures that targeted high-risk antibiotic agents (ie, restriction of fluoroquinolones), infection control practices, and environmental hygiene. RESULTS A total of 318 cases of CDI were identified during the outbreak, which was the result of the interaction between C. difficile ribotype 027 being introduced into the affected hospitals for the first time and other predisposing risk factors (ranging from host factors to suboptimal compliance with antibiotic guidelines and infection control policies). The 30-day all-cause mortality rate was 24.5%; however, CDI was the attributable cause of death for only 2.5% of the infected patients. Time series analysis showed that restricting the use of fluoroquinolones was associated with a significant reduction in the incidence of CDI (coefficient, -0.054; lag time, 4 months; P = .003). CONCLUSION These findings provide additional evidence to support the value of antimicrobial stewardship as an essential element of multifaceted interventions to control CDI outbreaks. The present CDI outbreak was ended following the implementation of an action plan improving communication, antibiotic stewardship, infection control practices, environmental hygiene, and surveillance.


British Journal of Clinical Pharmacology | 2012

The impact of antibiotic use on the incidence and resistance pattern of extended‐spectrum beta‐lactamase‐producing bacteria in primary and secondary healthcare settings

Mamoon A. Aldeyab; Stéphan Juergen Harbarth; Nathalie Vernaz; Mary P. Kearney; Michael G. Scott; Feras W. Darwish Elhajji; Motasem A. Aldiab; James McElnay

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The emergence and spread of bacteria producing extended-spectrum beta-lactamases (ESBLs) has important therapeutic and epidemiologic implications. • A key target for the establishment of hospital antibiotic stewardship is reducing the occurrence of additional antibiotic resistance. • Further research is needed to accumulate supporting evidence that reducing antibiotic use will result in a parallel reduction in antibiotic resistance. WHAT THIS STUDY ADDS • Fluoroquinolone restriction reversed ciprofloxacin resistance in primary and secondary healthcare settings. • Fluoroquinolone restriction reduced ESBL-producing bacteria incidence rates in both the primary and secondary healthcare settings. • This study highlights the value of time-series analysis in designing efficient antibiotic stewardship. AIMS The objective of the present study was to study the relationship between hospital antibiotic use, community antibiotic use and the incidence of extended-spectrum beta-lactamase (ESBL)-producing bacteria in hospitals, while assessing the impact of a fluoroquinolone restriction policy on ESBL-producing bacteria incidence rates. METHODS The study was retrospective and ecological in design. A multivariate autoregressive integrated moving average (ARIMA) model was built to relate antibiotic use to ESB-producing bacteria incidence rates and resistance patterns over a 5 year period (January 2005-December 2009). RESULTS Analysis showed that the hospital incidence of ESBLs had a positive relationship with the use of fluoroquinolones in the hospital (coefficient = 0.174, P= 0.02), amoxicillin-clavulanic acid in the community (coefficient = 1.03, P= 0.03) and mean co-morbidity scores for hospitalized patients (coefficient = 2.15, P= 0.03) with various time lags. The fluoroquinolone restriction policy was implemented successfully with the mean use of fluoroquinolones (mainly ciprofloxacin) being reduced from 133 to 17 defined daily doses (DDDs)/1000 bed days (P < 0.001) and from 0.65 to 0.54 DDDs/1000 inhabitants/day (P= 0.0007), in both the hospital and its surrounding community, respectively. This was associated with an improved ciprofloxacin susceptibility in both settings [ciprofloxacin susceptibility being improved from 16% to 28% in the community (P < 0.001)] and with a statistically significant reduction in ESBL-producing bacteria incidence rates. DISCUSSION This study supports the value of restricting the use of certain antimicrobial classes to control ESBL, and demonstrates the feasibility of reversing resistance patterns post successful antibiotic restriction. The study also highlights the potential value of the time-series analysis in designing efficient antibiotic stewardship.


Infection Control and Hospital Epidemiology | 2011

An Evaluation of the Impact of a Single-Dose Intravenous Immunoglobulin Regimen in the Treatment of Clostridium difficile Infections

Mamoon A. Aldeyab; James McElnay; Michael G. Scott; Elizabeth Davies; Collette Edwards; Feras W. Darwish Elhajji; Geraldine Conlon; Fidelma A. Magee; Paul J. Barr; Mary P. Kearney

Treatment of Clostridium difficile Infections • Author(s): Mamoon A. Aldeyab, PhD; James C. McElnay, PhD; Michael G. Scott, PhD; Elizabeth Davies, MB, BCH, BAO, FRCPath; Collette Edwards, BSc; Feras W. Darwish Elhajji, MSc; Geraldine Conlon, MSc; Fidelma A. Magee, BSc; Paul J. Barr, PhD; Mary P. Kearney, MB, BCH, BAO, FRCPath Source: Infection Control and Hospital Epidemiology, Vol. 32, No. 6 (June 2011), pp. 631-633 Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America Stable URL: http://www.jstor.org/stable/10.1086/660203 . Accessed: 18/05/2014 15:11


Journal of Antimicrobial Chemotherapy | 2014

A modified method for measuring antibiotic use in healthcare settings: implications for antibiotic stewardship and benchmarking

Mamoon A. Aldeyab; James McElnay; Michael G. Scott; William J. Lattyak; Feras W. Darwish Elhajji; Motasem A. Aldiab; Fidelma A. Magee; Geraldine Conlon; Mary P. Kearney

OBJECTIVES To determine whether adjusting the denominator of the common hospital antibiotic use measurement unit (defined daily doses/100 bed-days) by including age-adjusted comorbidity score (100 bed-days/age-adjusted comorbidity score) would result in more accurate and meaningful assessment of hospital antibiotic use. METHODS The association between the monthly sum of age-adjusted comorbidity and monthly antibiotic use was measured using time-series analysis (January 2008 to June 2012). For the purposes of conducting internal benchmarking, two antibiotic usage datasets were constructed, i.e. 2004-07 (first study period) and 2008-11 (second study period). Monthly antibiotic use was normalized per 100 bed-days and per 100 bed-days/age-adjusted comorbidity score. RESULTS Results showed that antibiotic use had significant positive relationships with the sum of age-adjusted comorbidity score (P = 0.0004). The results also showed that there was a negative relationship between antibiotic use and (i) alcohol-based hand rub use (P = 0.0370) and (ii) clinical pharmacist activity (P = 0.0031). Normalizing antibiotic use per 100 bed-days contributed to a comparative usage rate of 1.31, i.e. the average antibiotic use during the second period was 31% higher than during the first period. However, normalizing antibiotic use per 100 bed-days per age-adjusted comorbidity score resulted in a comparative usage rate of 0.98, i.e. the average antibiotic use was 2% lower in the second study period. Importantly, the latter comparative usage rate is independent of differences in patient density and case mix characteristics between the two studied populations. CONCLUSIONS The proposed modified antibiotic measure provides an innovative approach to compare variations in antibiotic prescribing while taking account of patient case mix effects.


Biomedical Reports | 2017

Chlorpheniramine and escitalopram: Similar antidepressant and nitric oxide lowering roles in a mouse model of anxiety

Omar Salem Gammoh; Fadia Mayyas; Feras W. Darwish Elhajji

There is a crosstalk between mood disorders and oxidative stress. Chlorpheniramine (CPA), a first generation antihistamine, is hypothesized to have an anxiolytic role at high doses; however, its antidepressant and antioxidant roles have not previously been investigated. The aim of the current study was to evaluate the antidepressant and anxiolytic effects of CPA treatment in association with nitric oxide (NO) and super oxide dismutase (SOD) activity in a mouse model of anxiety. BALB/c mice were divided into unstressed (naïve), control, and CPA- (0.5 mg/kg) and escitalopram- (ESC; 10 mg/kg) treated groups for 3 weeks. Subsequently, they were immobilized for 6 h and subjected to behavioural paradigms as follows: The open field test, the elevated plus maze (EPM) and the forced swim test to investigate motor function, anxiety and depression, respectively. The mice were sacrificed and serum was obtained to detect NO and SOD activity. Compared with the control group, the CPA-treated group demonstrated an antidepressant effect similar to that of the ESC-treated group. In addition, CPA prevented stress-induced NO without affecting SOD activity. CPA did not improve anxiety-like behaviour in the EPM, nor did it improve stress-induced locomotion and rearing, as demonstrated by the OFT. Thus, to the best of our knowledge, this is the first study to evaluate the antidepressant role of CPA in association with NO metabolism. However, further studies are required to elucidate the underlying mechanism.


Journal of pharmacy and nutrition sciences | 2014

Doctor of Pharmacy in Jordan: Students' Career Choices, Perceptions and Expectations

Nadine N. Abdelhadi; Mayyada Wazaify; Feras W. Darwish Elhajji; Iman A. Basheti


Journal of The Saudi Pharmaceutical Society | 2018

Animal use in pharmacy undergraduate pharmacology laboratories: Students’ perceptions and need assessments

Feras W. Darwish Elhajji; Iman A. Basheti


Aaps Pharmscitech | 2017

Influence of Testing Parameters on In Vitro Tramadol Release from Poloxamer Thermogels using the Immersion Cell Method

Lorina Bisharat; Diego Romano Perinelli; Alberto Berardi; Giulia Bonacucina; Serena Logrippo; Feras W. Darwish Elhajji; Marco Cespi; Giovanni Filippo Palmieri


World Academy of Science, Engineering and Technology, International Journal of Nutrition and Food Engineering | 2016

Evaluation of the Level of Knowledge about Probiotics amongst Community Pharmacy Staff in Jordan

Feras W. Darwish Elhajji; Alberto Berardi; Manal Ayyash; Iman A. Basheti

Collaboration


Dive into the Feras W. Darwish Elhajji's collaboration.

Top Co-Authors

Avatar

James McElnay

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Mamoon A. Aldeyab

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Mary P. Kearney

Northern Health and Social Care Trust

View shared research outputs
Top Co-Authors

Avatar

Michael G. Scott

Northern Health and Social Care Trust

View shared research outputs
Top Co-Authors

Avatar

Fidelma A. Magee

Northern Health and Social Care Trust

View shared research outputs
Top Co-Authors

Avatar

Geraldine Conlon

Northern Health and Social Care Trust

View shared research outputs
Top Co-Authors

Avatar

Iman A. Basheti

Applied Science Private University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Collette Edwards

Northern Health and Social Care Trust

View shared research outputs
Top Co-Authors

Avatar

Elizabeth Davies

Northern Health and Social Care Trust

View shared research outputs
Researchain Logo
Decentralizing Knowledge